Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study

Wang, K; Guo, Wei-Xing; Li, N; Shi, Jie; Zhang, C; Lau, W. Y.; Wu, Mengchao; Cheng, Shuqun

doi:10.1038/bjc.2014.102

Cited by 50 publications

(66 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Phosphotyrosine interaction domain containing one (PID1) function as a growth-inhibitory gene in brain tumors 38 and is a potent intracellular inhibitor of the insulin signaling pathway during obesity in humans and mice. 39 Fucosidase, alpha-L-1, tissue (FUCA1) is a liposomal enzyme that degrades a variety of fucosecontaining fucoglycoconjugates and has been proposed as a promising tumor marker in the diagnosis 40 and prognosis 41 of hepatocellular carcinoma. Finally, G protein-coupled receptor 15 (GPR15) acts as a chemokine receptor for human immunodeficiency virus.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease

Obeidat

Ding

Fishbane

et al. 2016

NICTOB

View full text Add to dashboard Cite

Introduction: Smoking is the number one modifiable environmental risk factor for chronic obstructive pulmonary disease (COPD). Clinical, epidemiological and increasingly "omics" studies assess or adjust for current smoking status using only self-report, which may be inaccurate. Objective measures such as exhaled carbon monoxide (eCO) may also be problematic owing to limitations in the measurements and the relatively short half life of the molecule. In this study, we determined the impact of different case definitions of current cigarette smoking on gene expression in peripheral blood of patients with COPD. Methods: Peripheral blood gene expression from 573 former-and current-smokers with COPD in the ECLIPSE study was used to find genes whose expression was associated with smoking status. Current smoking was defined using self-report, eCO concentrations, or both. Linear regression was used to determine the association of current smoking status with gene expression adjusting for age, sex and propensity score. Pathway enrichment analyses were performed on genes with P < .001. Result: Using self-report or eCO, only two genes were differentially expressed between current and ex-smokers, with no enrichment in biological processes. When current smoking was defined using both eCO and self-report, four genes were differentially expressed (LRRN3, PID1, FUCA1, GPR15) with enrichment in 40 biological pathways related to metabolic processes, response to hypoxia and hormonal stimulus. Additionally, the combined definition provided better distributions of test statistics for differential gene expression. Conclusion: A combined phenotype of eCO and self report allows for better discovery of genes and pathways related to current smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease

Obeidat

Ding

Fishbane

et al. 2016

NICTOB

View full text Add to dashboard Cite

show abstract

“…Its expression increases with liver insult similar to chronic hepatitis, cirrhosis, and HCC patients. 85 It is one of the early HCC biomarkers and has a cut-off value of 870 nm/mL/h. Interestingly, it is raised preceding six months of development of HCC, and its value is over 700 nm/mL/h in 85% of HCC patients.…”

Section: Serum Biomarkers Of Hccmentioning

confidence: 99%

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma

Chauhan

Lahiri

2016

Biomark�Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is offering a challenge to human beings, with the current modes of treatment being a palliative approach. Lack of proper curative or preventive treatment methods encouraged extensive research around the world with an aim to detect a vaccine or therapeutic target biomolecule that could lead to development of a drug or vaccine against HCC. Biomarkers or biological disease markers have emerged as a potential tool as drug/vaccine targets, as they can accurately diagnose, predict, and even prevent the diseases. Biomarker expression in tissue, serum, plasma, or urine can detect tumor in very early stages of its development and monitor the cancer progression and also the effect of therapeutic interventions. Biomarker discoveries are driven by advanced techniques, such as proteomics, transcriptomics, whole genome sequencing, micro- and micro-RNA arrays, and translational clinics. In this review, an overview of the potential of tissue- and serum-associated HCC biomarkers as diagnostic, prognostic, and therapeutic targets for drug development is presented. In addition, we highlight recently developed micro-RNA, long noncoding RNA biomarkers, and single-nucleotide changes, which may be used independently or as complementary biomarkers. These active investigations going on around the world aimed at conquering HCC might show a bright light in the near future.

show abstract

“…FUCA2 has been found to be essential for Helicobacter pylori adhesion during its infection of gastric cells (16). ␣-Fucosidases are also of considerable clinical interest because the presence of ␣-fucosidase activity in serum has been used in the diagnosis for hepatocellular cancers for decades (17).…”

mentioning

confidence: 99%

Identification and characterization of a core fucosidase from the bacterium Elizabethkingia meningoseptica

Hou

et al. 2018

Journal of Biological Chemistry

View full text Add to dashboard Cite

All reported α-l-fucosidases catalyze the removal of nonreducing terminal l-fucoses from oligosaccharides or their conjugates, while having no capacity to hydrolyze core fucoses in glycoproteins directly. Here, we identified an α-fucosidase from the bacterium with catalytic activity against core α-1,3-fucosylated substrates, and we named it core fucosidase I (cFase I). Using site-specific mutational analysis, we found that three acidic residues (Asp-242, Glu-302, and Glu-315) in the predicted active pocket are critical for cFase I activity, with Asp-242 and Glu-315 acting as a pair of classic nucleophile and acid/base residues and Glu-302 acting in an as yet undefined role. These findings suggest a catalytic mechanism for cFase I that is different from known α-fucosidase catalytic models. In summary, cFase I exhibits glycosidase activity that removes core α-1,3-fucoses from substrates, suggesting cFase I as a new tool for glycobiology, especially for studies of proteins with core fucosylation.

show abstract

Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study

Cited by 50 publications

References 42 publications

The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease

The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma

Identification and characterization of a core fucosidase from the bacterium Elizabethkingia meningoseptica

Contact Info

Product

Resources

About